Industry-sponsored "Expert committee recommendations for acne management" promote expensive drugs on the basis of weak evidence [5]

Pediatrics

Volumn 119, Issue 3, 2007, Pages 650-

  Newman, Thomas B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; GENERIC DRUG; PETROLEUM; RETINOIC ACID; RETINOID DERIVATIVE; DERMATOLOGICAL AGENT; RETINOID;

ACNE; CLINICAL TRIAL; DRUG COST; DRUG INDUSTRY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FUNDING; HUMAN; LETTER; MEDICAL EXPERT; MEDICAL INFORMATION; MEDICAL LITERATURE; PRIORITY JOURNAL; SKIN IRRITATION; ACNE VULGARIS; ADOLESCENT; CONFLICT OF INTEREST; ECONOMICS; NOTE;

ACNE VULGARIS; ADOLESCENT; BENZOYL PEROXIDE; CONFLICT OF INTEREST; DERMATOLOGIC AGENTS; DRUG COSTS; DRUG INDUSTRY; HUMANS; RETINOIDS;

EID: 33947178297     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-3041     Document Type: Letter

References (4)

1. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics. 2006;118:1188-1199
2. Gupta AK, Lynde CW, Kunynetz RA, Amin S, Choi K, Goldstein E. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/ erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg. 2003;7:31-37
3. Belknap BS. Treatment of acne with 5% benzoyl peroxide gel or 0.05% retinoic acid cream. Cutis. 1979;23:856-859
4. Lyons RE. Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. Int J Dermatol. 1978;17:246-251